QIAGEN NV provides sample-to-knowledge solutions that transform biological materials into molecular knowledge globally. The company is headquartered in Venlo, the Netherlands.
| Revenue (TTM) | $2.10B |
| Gross Profit (TTM) | $1.39B |
| EBITDA | $727.68M |
| Operating Margin | 23.80% |
| Return on Equity | 11.90% |
| Return on Assets | 6.01% |
| Revenue/Share (TTM) | $10.18 |
| Book Value | $16.15 |
| Price-to-Book | 2.54 |
| Price-to-Sales (TTM) | 4.16 |
| EV/Revenue | 4.513 |
| EV/EBITDA | 13.64 |
| Quarterly Earnings Growth (YoY) | -23.80% |
| Quarterly Revenue Growth (YoY) | 1.80% |
| Shares Outstanding | $206.25M |
| Float | $204.78M |
| % Insiders | 0.47% |
| % Institutions | 80.85% |
Volatility is currently contracting
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GERMANTOWN, Md., & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today highlighted its portfolio of molecular testing solutions supporting the public health response to the growing number of cyclosporiasis cases reported across the United States. More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May, along with another 7,000 potential cases, as health authorities investigate multiple outbreaks involving Cyclospora cayetanensis,.
VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel, establishing a comprehensive bloodstream infection testing offering on the QIAstat-Dx platform in Europe. The new QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance (AMR) markers from positive blood cultures in about one hour. It comp.
Qiagen is drawing early takeover interest from buyout firms, including EQT AB , Advent and KKR , Bloomberg News said on Thursday, citing people familiar with the matter.
Qiagen N.V. (QGEN) Shareholder/Analyst Call Transcript
Qiagen N.V. (QGEN) Discusses Digital PCR Technology and Applications in Environmental Sample Analysis Transcript
QGEN's QIAcuity expansion adds gene expression assays, multiplexing, automation and analysis tools to drive dPCR adoption.
VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its QIAcuity digital PCR (dPCR) ecosystem, with a focus on expanding gene expression capabilities, broadening assay content and enhancing workflow standardization to support the growing adoption of dPCR across life sciences and biopharma applications. As researchers increasingly seek higher sensitivity, greater precision and improved multiplexing capabi.
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?
NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. ("Qiagen" or the "Company") (NYSE: QGEN).
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on QGEN and any ticker you trade — then tracks every position and per-strategy win rate.
